XENON PHARMACEUTICALS INC. Long-Term Debt, Maturity, Year Two
XENON PHARMACEUTICALS INC. (XENE) had Long-Term Debt, Maturity, Year Two of $6.20 million as of 2019-12-31, per its 10-K filed 2020-03-09.
Discontinued › Notes › Commitment and Contingencies › Long-Term Debt, Fiscal Year Maturity › Long-Term Debt, Maturity, Year Two and Three
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo · last filed 2020-03-09
- 2019-12-31: Long-Term Debt, Maturity, Year Two $6.20M.
- 2019-09-30: Long-Term Debt, Maturity, Year Two $5.17M.
- 2019-06-30: Long-Term Debt, Maturity, Year Two $5.17M.
- 2019-03-31: Long-Term Debt, Maturity, Year Two $5.17M.
| Period end | Long-Term Debt, Maturity, Year Two |
|---|---|
| 2019-12-31 | $6.20M 10-K · filed 2020-03-09 |
| 2019-09-30 | $5.17M 10-Q · filed 2019-11-05 |
| 2019-06-30 | $5.17M 10-Q · filed 2019-08-06 |
| 2019-03-31 | $5.17M 10-Q · filed 2019-05-07 |
| 2018-12-31 | $5.17M 10-K · filed 2019-03-06 |
| 2018-03-31 | $2.80M 10-Q · filed 2018-05-08 |
| 2017-12-31 | $2.80M 10-K · filed 2018-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 |